Last reviewed · How we verify

LianHuaQingWen Granules

Guizhou Bailing Group Pharmaceutical Co Ltd · FDA-approved active Small molecule Quality 1/100

LianHuaQingWen Granules is a Small molecule drug developed by Guizhou Bailing Group Pharmaceutical Co Ltd. It is currently FDA-approved. Also known as: Lianhua Qingwen Keli.

At a glance

Generic nameLianHuaQingWen Granules
Also known asLianhua Qingwen Keli
SponsorGuizhou Bailing Group Pharmaceutical Co Ltd
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about LianHuaQingWen Granules

What is LianHuaQingWen Granules?

LianHuaQingWen Granules is a Small molecule drug developed by Guizhou Bailing Group Pharmaceutical Co Ltd.

Who makes LianHuaQingWen Granules?

LianHuaQingWen Granules is developed and marketed by Guizhou Bailing Group Pharmaceutical Co Ltd (see full Guizhou Bailing Group Pharmaceutical Co Ltd pipeline at /company/guizhou-bailing-group-pharmaceutical-co-ltd).

Is LianHuaQingWen Granules also known as anything else?

LianHuaQingWen Granules is also known as Lianhua Qingwen Keli.

What development phase is LianHuaQingWen Granules in?

LianHuaQingWen Granules is FDA-approved (marketed).

Related